AlzChem Group AG (ALZCF) Q3 2026 Earnings Call Transcript

Impact · against what's priced in

AlzChem demonstrates positive operational leverage with EBITDA growth (8%) outpacing revenue growth (4%) for the first nine months of 2026. Strong demand in Specialty Chemicals, specifically Human Nutrition and defense, suggests potential upside for full-year EPS estimates.

ALZCF+0.60

No priced-in read yet

In context

Revenue grew 4% to nearly EUR 444 million and EBITDA increased 8% to over EUR 93 million, indicating improved margins (21%) driven by Specialty Chemicals demand.

Read from the article alone

• earnings
• ALZCF
• defense
• ebitda
• germany
• human nutrition
• specialty chemicals
• transcript

Search tags